Vor Biopharma Inc. (VOR)
NASDAQ: VOR · Real-Time Price · USD
22.92
-0.09 (-0.39%)
Aug 18, 2026, 10:47 AM EDT - Market open
Vor Biopharma Employees
Vor Biopharma had 76 employees as of December 31, 2025. The number of employees decreased by 83 or -52.20% compared to the previous year.
Employees
76
Change
-83
Growth
-52.20%
Revenue / Employee
n/a
Profits / Employee
$8,260,289
Market Cap
1.36B
Employees Chart
| Date | Employees | Change (1Y) | Growth (1Y) |
|---|---|---|---|
| Dec 31, 2025 | 76 | -83 | -52.20% |
| Sep 30, 2025 | 154 | -5 | -3.14% |
| Jun 30, 2025 | 154 | - | - |
| Dec 31, 2024 | 159 | -9 | -5.36% |
| Dec 31, 2023 | 168 | 35 | 26.32% |
| Dec 31, 2022 | 133 | -2 | -1.48% |
| Dec 31, 2021 | 135 | 47 | 53.41% |
| Sep 30, 2021 | 122 | 52 | 74.29% |
| Jun 30, 2021 | 109 | 39 | 55.71% |
| Mar 31, 2021 | 92 | 22 | 31.43% |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Sep 30, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Jun 30, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
| Company Name | Employees |
|---|---|
| Novavax | 749 |
| Replimune Group | 465 |
| MeiraGTx Holdings | 409 |
| Monte Rosa Therapeutics | 173 |
| MoonLake Immunotherapeutics | 130 |
| Alpha Tau Medical | 121 |
| Inhibrx Biosciences | 110 |
| Cullinan Therapeutics | 109 |
VOR News
- 1 day ago - Vor Bio price target raised to $27 from $18 at Wedbush - TheFly
- 7 days ago - Vor Bio Reports Second Quarter 2026 Financial Results and Provides Corporate Update - GlobeNewsWire
- 7 days ago - Vor Biopharma Quarterly report: Q2 2026 - Filings
- 7 days ago - Vor Biopharma Earnings release: Q2 2026 - Filings
- 14 days ago - Vor Bio Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewsWire
- 5 weeks ago - Vor Bio Appoints David Zaccardelli to Board of Directors - GlobeNewsWire
- 2 months ago - Vor Bio announces China NMPA approval for telitacicept - TheFly
- 2 months ago - Telitacicept Receives NMPA Approval for the Treatment of Sjögren's Disease in China - GlobeNewsWire